Recurrence-Free and Overall Survival Better in Adult Patients With Colon Cancer
Patients older than 25 years have significantly higher rates of OS and RFS at 3 and 5 years compared with patients younger than 25.
Colorectal Cancer
Bariatric Surgery May Cut Risk for Colorectal Cancer in Obese Patients
Relative risk for developing colorectal cancer reduced by about 35 percent with bariatric surgery for obesity.
Adding Cetuximab to Chemotherapy Shortens Survival by 2 Years in Advanced CRC
Adding cetuximab to chemotherapy led to worse outcomes for patients with resectable liver metastases caused by colorectal cancer, updated data from the New EPOC trial showed.
Circulating Insulin-Like Growth Factor 1 Levels Linked to Colorectal Cancer
The study researchers concluded that higher circulating levels of IGF1 were associated with a higher risk for colorectal cancer and that lifestyle, diet, and/or pharmacological interventions that target the IGF system may help reduce disease risk.
Following Helicobacter pylori Infection, Gastric Cancer Risk High
Individuals who are racial or ethnic minorities and individuals who are smokers experience significantly higher risks for gastric cancer following a diagnosis of Helicobacter pylori infection.
Collagenolytic Microbes Associated With a Western Diet May Promote Tumor Formation After Colorectal Surgery
A mechanism was identified through which a Western diet and antibiotic use may be able to promote tumorigenesis by colon cancer cells after curative resection.
Steep Increase Seen in Incidence of CRC From Age 49 to 50 Years
Increases seen across the U.S., in men and women, in whites and blacks, for colon and rectal cancers.
Social Support Linked to Mortality in Older Women With CRC
Low and moderate perceived social support linked to higher mortality in postmenopausal women with CRC.
How Targeted Therapies Could Actually Promote Cancer Cell Mutability
Research shows how cancer cells can act like bacteria and adapt to increase their chances of survival.
Longer Maintenance of QoL in BRAF V600E-Mutant Metastatic Colorectal Cancer With Triplet Regimen vs an Irinotecan-Based Regimen
The randomized, phase 3 BEACON CRC trial was a 3-arm study conducted in patients with pretreated metastatic CRC characterized by a BRAF V600E mutation.
